<\/p>\n
The EMERGENT-2 phase III trial<\/a> met its primary objective by achieving a significant reduction in PANSS total score with oral KarXT (xanomeline-trospi) versus placebo in people with schizophrenia, Karuna Therapeutics announced.<\/p>\n Up to 87% of people with opioid use disorder<\/a> may not be receiving life-saving medications such as methadone, buprenorphine, and naltrexone. (International Journal of Drug Policy)<\/p>\n After 12 weeks, young people with anxiety resistant to cannabidiol treatment<\/a> had an average decrease of 42.6% in symptom severity. “Young people had fewer panic attacks and were able to do things they couldn’t do before,” said Paul Amminger, MD, PhD, of Orygen in Australia. (Journal of Clinical Psychiatry)<\/p>\n Often children of people with Alzheimer’s feel fear and anxiety<\/a> of his own diagnosis one day. (New York News)<\/p>\n After a negative review by an advisory committee earlier this year, the FDA rejected pimavanserin (Nuplazid)<\/a> for an additional indication for the treatment of hallucinations and delusions associated with the psychosis of Alzheimer’s disease, Acadia Pharmaceuticals said.<\/p>\n Children with genetic intellectual disability<\/a> had a much higher risk of developing neuropsychiatric conditions, according to the UK-based IMAGINE study. (The Lancet Psychiatry)<\/p>\n Older Americans still feel the mental burden of the covid-19 pandemic<\/a>. (the hill)<\/p>\n A Mendelian randomization study found that global cortical thickness could be used predict alcohol consumption<\/a> and excessive alcohol consumption behaviors. (JAMA Psychiatry)<\/p>\n <\/p>\n Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry and nephrology news. Based in the New York City office, he has been with the firm since 2015. <\/p>\n